XtalPi Recognized in Fortune China Tech 50 and Jiemian Cailian Annual Global Impact Rankings, Leading Scientific AI Transformation with AI+Robotics Platform

Recently, XtalPi, a platform-based enterprise empowering innovation in new drugs and new materials with artificial intelligence (AI) + robotics (2228.HK) consecutively ranked on two authoritative lists—Honored as one of the “2026 Fortune China Tech 50”and"Annual Enterprise" of the "2026 Annual Cases of Global Influence by Chinese Enterprises"Among them, the Fortune China Tech 50 list is published by the globally renowned business media outlet *Fortune* magazine, aiming to select tech companies that “were born in China and are influencing the world.”Other companies on the list include leading tech firms such as Huawei, Tencent, and Alibaba.The “Annual Case Studies of Chinese Enterprises’ Global Influence” were jointly released by Shanghai United Media Group, Jiemian-Cailianshe, and the China Enterprise Globalization Alliance (CEGA), among others.XtalPi and Industry Leaders Such as BYD Jointly Selected as “Enterprise of the Year”, and became the sole representative in the field of AI for Science (AI4Science) among the 16 award-winning companies.

XtalPi Sweeps Dual AwardsCross-validated by Two Authoritative Industry Rankings，Not only does it meanIts “AI + Robotics” R&D platform has garnered high acclaim from top-tier international business media, authoritative outlets, and independent institutions, further validating the solid implementation of the company’s global expansion strategy for its technology and the continuous rise of its global influence.The AI4Science track is accelerating from the technology validation phase into a new stage of large-scale industrial implementation, and XtalPi, as a leading enterprise in this field, is providing strong evidence and benchmark cases for this trend through its continuous global commercial achievements.

As a globally authoritative technology ranking, the Fortune China Tech 50 evaluates companies across multiple dimensions, including the depth of technological innovation, intensity of R&D investment, scale of industrial implementation, and industry influence, with listed companies representing benchmark forces in their respective sectors. The “Chinese Enterprises’ Global Influence Evaluation System” employs a rigorous dual mechanism of “data assessment + expert review” to select annual benchmark cases from hundreds of applications. It focuses on evaluating companies’ performance in dimensions such as “their leading role in industry development,” “breakthrough progress in key markets or fields,” and “sustainable capabilities in global layout,” making it a highly prestigious and authoritative certification in the field of overseas expansion. Both rankings focus on the real-world commercialization, engineering, and scalable implementation capabilities of Chinese enterprises in the global market. XtalPi has successfully passed the cross-validation of two independent reviews, earning dual authoritative recognitions.Further validates the company's achievements in global expansion, its technological innovation capabilities, and its value as an industry leader.

Currently, artificial intelligence technology has become the core engine reshaping the global competitive landscape, driving industrial transformation and upgrading, and leading high-quality development. XtalPi continues to spearhead the paradigm shift in AI + robotics R&D. The company’s independently developed automated chemical robotics cluster is continuously expanding its global leadership advantage.Over 300 robotic experimental workstations have been deployed across multiple locations worldwide, enabling unmanned 24/7 operation. This has increased laboratory personnel efficiency by 8-fold and data collection capacity by 50-fold, significantly improving the synthesis efficiency and success rate of new molecules.Building on this foundation, XtalPi has constructed a complete technological closed loop spanning “AI algorithms – Multi-Agent systems – robotic experimental workstations,” enabling AI not only to “compute” but also to directly drive parallel experiments in the physical world, thereby forming an iterative R&D capability characterized by autonomous decision-making and execution. This system is rapidly becoming a universal infrastructure in the field of AI4Science, deeply empowering source innovation in global biopharmaceuticals and new materials.

Leveraging this tripartite autonomous discovery framework of “Scientific AI, Physical AI, and Agentic System”, XtalPi continues to achieve breakthroughs in key sectors ranging from pharmaceuticals to new energy and advanced materials,Serving over 300 international enterprises and research institutions, having established a business network spanning core global markets. In the biopharmaceutical sector, the Company has partnered with 17 of the top 20 global pharmaceutical companies, securing high-value orders and achieving repeat purchases from industry giants such as Eli Lilly and Pfizer, as well as innovative biotech firms like DoveTree, andAdvancing the regulatory submissions and clinical trials of multiple candidate drugs with “First-in-class” and “Best-in-class” potential in the fields of cancer, rare diseases, and autoimmune diseases., continuously achieving the transformation of research outcomes; in the fields of new materials and new energy, XtalPi has partnered with industry leaders such as JinkoSolar, BASF, and Sinopec, as well as multiple leading research institutions, to explore cutting-edge practices in intelligent and automated AI-plus-robotics materials R&D, set industry benchmarks, and drive cross-scenario commercial implementation.Validated the sustained global deployment of its AI for Science new infrastructure.。

XtalPi has once again been honored on two prestigious lists: “Fortune China Tech 50” and “Annual Chinese Enterprises with Global Influence.”, which fully validates XtalPi’s core scientific and technological innovation capabilities, global competitiveness, and sustained growth momentum as a leading enterprise in China’s AI4Science sector. The company will continue to advance its global strategic layout, deepen source-level innovation in the biopharmaceutical and new materials industries, accelerate the translation of cutting-edge scientific achievements into real-world productivity, and collaborate with global partners to contribute Chinese solutions to the development of the global ecosystem and infrastructure for scientific intelligence.